Confirmed
One controlled phase 3 trial met its main goal, and ponesimod is approved for this use.
S1P receptor modulation (lymphocyte trafficking): reduce relapses and new lesions in relapsing and progressive MS
relapsing and progressive MS · S1P receptor modulation (lymphocyte trafficking)
Two or more controlled phase 3 trials met their main goal, or one did and a medicine of this approach is approved for this use.
- Trials
- 3
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 1133
Deciding trials (phase 3): 1 met, 0 did not.
Other linked trials: 2
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 3 · 2015 · Compared with teriflunomide · MSFT-NCT02425644
Other linked trials: 2
These linked trials do not set the status.
- OPTIMUM-LTNo result found
Phase 3 · 2017 · Not randomised
- POINTMissed main goal
Phase 3 · 2017 · Placebo-controlled
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-30Status changed from Mixed to Confirmed
- 2026-10-28Status changed from Confirmed to Mixed
- 2026-10-27First listed as Confirmed
Related hypotheses
- S1P receptor modulation (lymphocyte trafficking): reduce relapses and new lesions in primary progressive MS
- S1P receptor modulation (lymphocyte trafficking): reduce relapses and new lesions in relapsing MS
- S1P receptor modulation (lymphocyte trafficking): reduce relapses and new lesions in secondary progressive MS
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error